Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ESPR Esperion Therapeutics

Pre-Mkt 04-16 09:20:05 EDT

2.17

+0.12

+5.85%

盘前2.20

+0.03+1.38%

09:19 EDT

High2.17	Low2.04	Vol16.49M
Open2.05	D1 Closing2.05	Amplitude6.34%
Mkt Cap557.28M	Tradable Cap514.29M	Total Shares256.81M
T/O34.42M	T/O Rate6.96%	Tradable Shares237.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ESPR","market":"US","secType":"STK","nameCN":"Esperion Therapeutics","latestPrice":2.17,"timestamp":1776283200000,"preClose":2.05,"halted":0,"volume":16493188,"hourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.17,"latestTime":"09:19 EDT","volume":77550,"amount":170690.380575,"timestamp":1776345550151,"change":0.03,"changeRate":0.013825,"amplitude":0.016636},"delay":0,"changeRate":0.05853658536585372,"floatShares":237000000,"shares":256810500,"eps":-0.109118,"marketStatus":"Pre-Mkt","change":0.12,"latestTime":"04-16 09:20:05 EDT","open":2.05,"high":2.17,"low":2.04,"amount":34416724.6388368,"amplitude":0.063415,"askPrice":2.25,"askSize":56,"bidPrice":2.18,"bidSize":5862,"shortable":3,"etf":0,"ttmEps":-0.109118,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776346200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1372219200000,"exchange":"NASDAQ","adjPreClose":2.17,"preHourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.17,"latestTime":"09:19 EDT","volume":77550,"amount":170690.380575,"timestamp":1776345550151,"change":0.03,"changeRate":0.013825,"amplitude":0.016636},"postHourTrading":{"tag":"盘后","latestPrice":2.17,"preClose":2.17,"latestTime":"19:57 EDT","volume":160739,"amount":351560.9485,"timestamp":1776297464669,"change":0,"changeRate":0,"amplitude":0.032258},"volumeRatio":2.2283627818913736,"optionData":{"bulkOrders":[{"symbol":"ESPR","call":true,"expireDate":1781755200000,"strike":"3.5","timestamp":1776260955013,"price":0.15,"volume":4500,"amount":67500,"type":"-"}]},"impliedVol":1.2157,"impliedVolPercentile":0.8434},"requestUrl":"/m/hq/s/ESPR/tweets","defaultTab":"tweets","newsList":[{"id":"2627412222","title":"Esperion Therapeutics: Reinforced Buy Rating on Strengthened Investment Story and Conference-Driven Upside Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2627412222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627412222?lang=en_us&edition=fundamental","pubTime":"2026-04-14 18:15","pubTimestamp":1776161757,"startTime":"0","endTime":"0","summary":"Analyst Serge Belanger from Needham maintained a Buy rating on Esperion and keeping the price target at $5.00. Serge Belanger has given his Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/esperion-therapeutics-reinforced-buy-rating-on-strengthened-investment-story-and-conference-driven-upside-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/esperion-therapeutics-reinforced-buy-rating-on-strengthened-investment-story-and-conference-driven-upside-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624168068","title":"BRIEF-Athyrium Capital Management And Esperion Enter Into $50 Million Japan Royalty Financing To Support Strategic Acquisition Of Corstasis Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2624168068","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624168068?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:37","pubTimestamp":1775165838,"startTime":"0","endTime":"0","summary":"BRIEF-Athyrium Capital Management And Esperion Enter Into $50 Million Japan Royalty Financing To Support Strategic Acquisition Of Corstasis TherapeuticsApril 2 (Reuters) - Esperion Therapeutics Inc ES","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA6G6TRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624805686","title":"BRIEF-Esperion Therapeutics Enters First Amendment To Credit Agreement On April 2, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624805686","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624805686?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:33","pubTimestamp":1775165585,"startTime":"0","endTime":"0","summary":"BRIEF-Esperion Therapeutics Enters First Amendment To Credit Agreement On April 2, 2026 - SEC FilingApril 2  - Esperion Therapeutics Inc ESPR.O:ESPERION THERAPEUTICS INC - ENTERS FIRST AMENDMENT TO CREDIT AGREEMENT ON APRIL 2, 2026 - SEC FILINGESPERION THERAPEUTICS INC - INCURS $25 MILLION IN ADDITIONAL TERM LOANS ON APRIL 2, 2026 - SEC FILINGSource text: [ID:n0001628280-26-023196]Further company coverage: ESPR.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L12Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624268083","title":"BRIEF-Esperion Therapeutics Closes Acquisition Of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise With Enbumyst™ (Bumetanide Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624268083","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624268083?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:24","pubTimestamp":1775165081,"startTime":"0","endTime":"0","summary":"BRIEF-Esperion Therapeutics Closes Acquisition Of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise With Enbumyst (Bumetanide Nasal Spray)April 2 (Reuters) - Esperion Therapeutics Inc ESP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA15YZ8M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624682190","title":"Esperion Therapeutics Inc - Enters First Amendment to Credit Agreement on April 2, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682190?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:29","pubTimestamp":1775161757,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L12Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624682917","title":"Esperion, Athyrium Capital enter $50M royalty financing agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682917","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682917?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:16","pubTimestamp":1775160976,"startTime":"0","endTime":"0","summary":"Athyrium Capital and Esperion (ESPR) announced the entry into a $50M royalty financing agreement under which certain funds managed by Athyrium Capi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-athyrium-capital-enter-50m-royalty-financing-agreement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-athyrium-capital-enter-50m-royalty-financing-agreement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624864682","title":"Esperion enters $50 million Japan royalty financing with Athyrium Capital Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2624864682","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624864682?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:08","pubTimestamp":1775160520,"startTime":"0","endTime":"0","summary":"Athyrium funds will buy 100% of Esperion royalty interest on Japan net sales of Otsuka bempedoic acid products from Jan. 1, 2026, subject to a cap.Payments to Athyrium will include tiered royalties of 12% to 33% until it receives 2.0x its investment.Royalty rights will revert to Esperion once Athyrium reaches the 2.0x return threshold.Proceeds will support Esperion acquisition of Corstasis, which markets Enbumyst, an FDA-approved intranasal loop diuretic for edema.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLb93dhD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","ESPR","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4112","LU2095319765.USD","BK4588","BK4585","LU2210150020.SGD","BK4007","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624840566","title":"Esperion Therapeutics Inc - Athyrium Funds to Receive Tiered Royalties of 12%-33% and Milestone Payments Until 2.0X Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2624840566","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624840566?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:05","pubTimestamp":1775160301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA6G6TRN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624684052","title":"Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2624684052","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624684052?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:05","pubTimestamp":1775160301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA6G6TRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624684000","title":"Esperion Therapeutics Inc - Athyrium Funds to Buy 100% of Esperion's Royalty Interest on Otsuka's Japan Sales From Jan 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624684000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624684000?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:05","pubTimestamp":1775160301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA6G6TRN:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624024684","title":"Esperion Therapeutics Inc - Financing Supports Esperion's Acquisition of Corstasis Therapeutics, Developer of Enbumyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2624024684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624024684?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:05","pubTimestamp":1775160301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA6G6TRN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624768473","title":"Esperion closes acquisition of Corstasis, adds Enbumyst nasal spray diuretic","url":"https://stock-news.laohu8.com/highlight/detail?id=2624768473","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624768473?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:00","pubTimestamp":1775160030,"startTime":"0","endTime":"0","summary":"Esperion closed its acquisition of privately held Corstasis Therapeutics.Deal adds Enbumyst , an FDA-approved nasal spray loop diuretic, to Esperion’s cardiovascular franchise.Enbumyst received FDA clearance in September 2025 for edema tied to congestive heart failure, hepatic disease, or renal disease in adults.Esperion plans to use its cardiovascular commercial infrastructure to expand payer access and drive outpatient adoption of Enbumyst.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL8lKxpr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD","BK4588","SG9999014021.USD","SG9999014039.USD","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","ESPR","SG9999014013.SGD","NDAQ","BK4007","IE00B64PRP62.GBP","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623398584","title":"Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2623398584","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623398584?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958400,"startTime":"0","endTime":"0","summary":"ANN ARBOR, Mich., March  31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25th Annual Needham Virtual Healthcare Conference ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3265427/0/en/Esperion-to-Participate-in-25th-Annual-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","ESPR","LU0128526141.USD","XLV","BK4137","XBI","HCSG","LABU","BK4581","BK4585","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623588129","title":"Esperion Therapeutics: CLEAR Outcomes Stroke Data and Commercial Momentum Underscore Buy-Rated Cardiovascular Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2623588129","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623588129?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:38","pubTimestamp":1774953506,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Esperion. The associated price target remains the same with $16.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/esperion-therapeutics-clear-outcomes-stroke-data-and-commercial-momentum-underscore-buy-rated-cardiovascular-franchise-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/esperion-therapeutics-clear-outcomes-stroke-data-and-commercial-momentum-underscore-buy-rated-cardiovascular-franchise-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","CSII","BK4082","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623363317","title":"Esperion says CLEAR Outcomes analysis shows Nexletol cuts ischemic stroke risk 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623363317","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623363317?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:05","pubTimestamp":1774872340,"startTime":"0","endTime":"0","summary":"Esperion reported two post-hoc CLEAR Outcomes analyses already presented as moderated posters at ACC.26 in New Orleans held March 28-30, 2026.Stroke analysis showed bempedoic acid reduced ischemic stroke risk by 22% versus placebo in statin-intolerant patients.Autoimmune or inflammatory disease analysis found similar MACE benefit with bempedoic acid versus placebo in patients with prior autoimmune or inflammatory diseases compared with those without.Company positioned NEXLETOL bempedoic acid as a cardiovascular risk-reduction option for adults unable to take recommended statin therapy, citing recent inclusion in US dyslipidemia guidelines.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL9hTKXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4112","BK4007","LU0314104364.USD","LU2095319765.USD","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014021.USD","SG9999014005.SGD","ESPR","NDAQ","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623131783","title":"Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2623131783","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623131783?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":"– Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports Bempedoic Acid Reduced MACE in High-Risk Patie","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264581/0/en/Esperion-Showcases-New-Data-from-CLEAR-Outcomes-Highlighting-Value-of-NEXLETOL-bempedoic-acid-at-the-American-College-of-Cardiology-s-Annual-Scientific-Session-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","AFG","MACE","BK4007","BK4183","BK4157","ESPR","BK4117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620422421","title":"Get an Lp(a) test - and 3 other things you must do now for heart health","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422421?lang=en_us&edition=fundamental","pubTime":"2026-03-19 23:29","pubTimestamp":1773934140,"startTime":"0","endTime":"0","summary":"I'm a cardiologist. Here are the most important new guidelines that younger people need to know about when it comes to their heart health.Physicians are now urging younger adults to get screened for heart disease.We have all seen the headlines about deaths from heart disease rising in younger people.This has prompted many of us in preventive cardiology to question how well cardiovascular disease prevention is working if mortality is so high. How should we tackle the expected rise in heart disease in women and men?There are now new guidelines, which were published Friday by the American College of Cardiology and the American Heart Association, that will change how we think about cardiovascular disease prevention - and specifically cholesterol. We already know that lifetime exposure to high LDL, or low-density lipoprotein, increases cardiovascular risk, and that getting care earlier can help prevent heart disease. That's where the focus of cardiovascular care really needs to be.Low-densi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU1057294990.SGD","LU1917777945.USD","LU1061106388.HKD","LU0320765992.SGD","LU0823434740.USD","IE00B4R5TH58.HKD","BK4533","BK4588","BK4581","IE00BJT1NW94.SGD","REGN","LU0823416689.USD","LU2089984988.USD","IE0009355771.USD","AMGN","LU0289739699.SGD","LU2362541513.USD","LU1023059063.AUD","LU2242646821.SGD","IE0002141913.USD","LU0882574055.USD","LU2362541273.HKD","IE00BFTCPJ56.SGD","LU2023250504.SGD","ESPR","LU0058720904.USD","LU0868494617.USD","LU0053666078.USD","LU2237438978.USD","LU0109394709.USD","LU2106854487.HKD","LU2468319806.SGD","LU1974910355.USD","LU0823434583.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","IE00B2B36J28.USD","LU1571399168.USD","BK4599","BK4534","LU2112291526.USD","BK4007","BK4585","LU1983299246.USD","BK4566","LU0889565916.HKD","LU2242652126.USD","LU2362540622.SGD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620421040","title":"Esperion to present two CLEAR Outcomes analyses at ACC 2026 Annual Scientific Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2620421040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620421040?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:03","pubTimestamp":1773749011,"startTime":"0","endTime":"0","summary":"Esperion will attend the American College of Cardiology 2026 Annual Scientific Session  in New Orleans on March 28-30, 2026. Esperion plans to present an analysis on bempedoic acid and stroke incidence on March 28, 2026. It also plans to present an analysis on cardiovascular outcomes in patients with autoimmune or inflammatory diseases on March 29, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2rYvFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4007","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4585","IE00B3QW5Z07.USD","ESPR","BK4588","LU2095319765.USD","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","IE00BKPKM429.USD","IE00BN0W2V16.EUR","NDAQ","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619452993","title":"Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452993?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:51","pubTimestamp":1773658305,"startTime":"0","endTime":"0","summary":"Esperion (ESPR) welcomed the inclusion of bempedoic acid for LDL-C lowering and cardiovascular risk reduction in the 2026 Americal College of Cardi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-says-bempedoic-acid-receives-recommendations-in-acc-aha-guideline-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-says-bempedoic-acid-receives-recommendations-in-acc-aha-guideline-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619454364","title":"Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2619454364","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619454364?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:30","pubTimestamp":1773657000,"startTime":"0","endTime":"0","summary":"– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolem","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256088/0/en/Esperion-s-Bempedoic-Acid-Receives-Multiple-Class-1-Recommendations-in-2026-ACC-AHA-Multisociety-Guideline-for-Management-of-Dyslipidemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4007","ESPR","CAC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.esperion.com","stockEarnings":[{"period":"1week","weight":-0.0687},{"period":"1month","weight":-0.1933},{"period":"3month","weight":-0.3067},{"period":"6month","weight":-0.2109},{"period":"1year","weight":1.1794},{"period":"ytd","weight":-0.4135}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.043403},{"month":2,"riseRate":0.461538,"avgChangeRate":0.113863},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.039729},{"month":4,"riseRate":0.384615,"avgChangeRate":-0.041954},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.032489},{"month":6,"riseRate":0.75,"avgChangeRate":0.035061},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.001019},{"month":8,"riseRate":0.461538,"avgChangeRate":0.026549},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.000828},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.017419},{"month":11,"riseRate":0.692308,"avgChangeRate":0.148542},{"month":12,"riseRate":0.461538,"avgChangeRate":0.067177}],"exchange":"NASDAQ","name":"Esperion Therapeutics","nameEN":"Esperion Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Esperion Therapeutics,ESPR,Esperion Therapeutics股票,Esperion Therapeutics股票老虎,Esperion Therapeutics股票老虎国际,Esperion Therapeutics行情,Esperion Therapeutics股票行情,Esperion Therapeutics股价,Esperion Therapeutics股市,Esperion Therapeutics股票价格,Esperion Therapeutics股票交易,Esperion Therapeutics股票购买,Esperion Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}